Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

89bio

Nasdaq:ETNB
Snowflake Description

Flawless balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ETNB
Nasdaq
$443M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of liver and cardio-metabolic diseases. The last earnings update was 10 days ago. More info.


Add to Portfolio Compare Print
  • 89bio has significant price volatility in the past 3 months.
ETNB Share Price and Events
7 Day Returns
36.4%
NasdaqGM:ETNB
5.2%
US Biotechs
10.5%
US Market
1 Year Returns
-
NasdaqGM:ETNB
0%
US Biotechs
-11.5%
US Market
ETNB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
89bio (ETNB) 36.4% -4.3% 30.3% - - -
US Biotechs 5.2% -6.5% -8.7% 0% 6.2% -10.4%
US Market 10.5% -15.4% -21.4% -11.5% 5.4% 18.1%
1 Year Return vs Industry and Market
  • No trading data on ETNB.
  • No trading data on ETNB.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

ETNB Value

 Is 89bio undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for 89bio. This is due to cash flow or dividend data being unavailable. The share price is $32.11.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for 89bio's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are 89bio's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:ETNB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-24.49
NasdaqGM:ETNB Share Price ** NasdaqGM (2020-03-27) in USD $32.11
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.4x
United States of America Market PE Ratio Median Figure of 2,939 Publicly-Listed Companies 12.96x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of 89bio.

NasdaqGM:ETNB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:ETNB Share Price ÷ EPS (both in USD)

= 32.11 ÷ -24.49

-1.31x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • 89bio is loss making, we can't compare its value to the US Biotechs industry average.
  • 89bio is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does 89bio's expected growth come at a high price?
Raw Data
NasdaqGM:ETNB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.31x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
-13%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.96x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for 89bio, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on 89bio's assets?
Raw Data
NasdaqGM:ETNB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $6.52
NasdaqGM:ETNB Share Price * NasdaqGM (2020-03-27) in USD $32.11
United States of America Biotechs Industry PB Ratio Median Figure of 429 Publicly-Listed Biotechs Companies 2.53x
United States of America Market PB Ratio Median Figure of 5,148 Publicly-Listed Companies 1.26x
NasdaqGM:ETNB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:ETNB Share Price ÷ Book Value per Share (both in USD)

= 32.11 ÷ 6.52

4.92x

* Primary Listing of 89bio.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • 89bio is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess 89bio's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. 89bio has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ETNB Future Performance

 How is 89bio expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-13%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is 89bio expected to grow at an attractive rate?
  • Unable to compare 89bio's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare 89bio's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare 89bio's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:ETNB Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:ETNB Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts -13%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:ETNB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:ETNB Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 55 -102 -95 3
2023-12-31 3 -97 -122 3
2022-12-31 3 -78 -97 3
2021-12-31 0 -56 -71 3
2020-12-31 0 -57 -63 3
2020-03-28
NasdaqGM:ETNB Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -25 -57
2019-09-30 -19 -44
2019-06-30 -15 -30
2018-12-31 -14 -18

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • 89bio is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if 89bio is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:ETNB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from 89bio Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:ETNB Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -3.87 -1.69 -6.05 2.00
2023-12-31 -5.01 -3.03 -6.98 2.00
2022-12-31 -4.26 -2.48 -6.03 2.00
2021-12-31 -3.36 -1.60 -5.11 2.00
2020-12-31 -4.42 -4.42 -4.42 1.00
2020-03-28
NasdaqGM:ETNB Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -24.49
2019-09-30 -72.33
2019-06-30 -48.57
2018-12-31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if 89bio will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess 89bio's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
89bio has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ETNB Past Performance

  How has 89bio performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare 89bio's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • 89bio does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare 89bio's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare 89bio's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
89bio's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from 89bio Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:ETNB Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -57.42 5.29 21.35
2019-09-30 -44.25 3.73 19.09
2019-06-30 -29.69 2.70 15.70
2018-12-31 -17.65 1.62 14.92

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if 89bio has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if 89bio has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if 89bio improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess 89bio's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
89bio has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ETNB Health

 How is 89bio's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up 89bio's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • 89bio is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • 89bio has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of 89bio's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • 89bio has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from 89bio Company Filings, last reported 2 months ago.

NasdaqGM:ETNB Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 89.94 0.00 93.34
2019-09-30 11.79 0.00 16.19
2019-06-30 18.72 0.00 21.92
2018-12-31 8.69 0.00 11.23
  • 89bio has no debt.
  • 89bio has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • 89bio has sufficient cash runway for more than 3 years based on current free cash flow.
  • 89bio has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 61.2% each year.
X
Financial health checks
We assess 89bio's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. 89bio has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ETNB Dividends

 What is 89bio's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from 89bio dividends. Estimated to be 0% next year.
If you bought $2,000 of 89bio shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate 89bio's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate 89bio's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:ETNB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1949 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:ETNB Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as 89bio has not reported any payouts.
  • Unable to verify if 89bio's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of 89bio's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as 89bio has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of 89bio's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess 89bio's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can 89bio afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. 89bio has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ETNB Management

 What is the CEO of 89bio's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Rohan Palekar
COMPENSATION $1,022,611
AGE 53
TENURE AS CEO 1.8 years
CEO Bio

Mr. Rohan Palekar seves as the Chief Executive Officer and Director at 89bio, Inc. since June 2018. Mr. Palekar served as the Chief Executive Officer and President of Avanir Pharmaceuticals, Inc. since January 20, 2016 a specialty pharmaceutical company, from December 2015 to July 2017, where he led the company following its acquisition by Otsuka Pharmaceutical Co., Ltd. in 2015. Mr. Palekar served as Chief Operating Officer and Executive Vice President of Avanir Pharmaceuticals, Inc. from March 2015 to January 20, 2016. He served as Chief Commercial Officer and Senior Vice President of Avanir Pharmaceuticals, Inc. since March 16, 2012 until March 2015. Mr. Palekar served as Chief Commercial Officer of Medivation Inc. since January 2008 until September 2, 2011. He leads all pre and post approval commercial activities for Medivation's product candidates Dimebon(TM), in clinical development for the treatment of Alzheimer's and Huntington's diseases, and MDV3100, in clinical development for the treatment of hormone-refractory prostate cancer. He held various positions at Johnson & Johnson family of companies. Mr. Palekar has vast of experience in the biopharmaceutical industry and has worked on significant brands including Remicade(R) and Stelara(R), as well as the investigational therapy MDV3100. From 2005 to December 2007, he served as Vice President of sales and marketing-dermatology at Centocor Inc., where he launched Remicade(R), a multi-billion dollar anti-TNF antibody, in two new indications that established the brand and company in the dermatology field. Prior to that, Mr. Palekar served as Worldwide Vice President of Global Biologics Strategic Marketing of Centocor, where he led commercialization efforts for a portfolio of more than ten compounds targeting multiple indications. Mr. Palekar was the worldwide Vice President of immunology and held marketing leadership roles at McNeil Consumer and Specialty Pharmaceuticals. He also served as a member of the Johnson & Johnson Pharmaceuticals Group Marketing Excellence Steering Committee. Mr. Palekar holds a Bachelor of Commerce and a of General Laws from the University of Bombay and a Master of Business Administration from the Amos Tuck School of Business Administration at Dartmouth College.

CEO Compensation
  • Rohan's compensation has increased whilst company is loss making.
  • Rohan's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the 89bio management team in years:

1.3
Average Tenure
52
Average Age
  • The average tenure for the 89bio management team is less than 2 years, this suggests a new team.
Management Team

Rohan Palekar

TITLE
CEO & Director
COMPENSATION
$1M
AGE
53
TENURE
1.8 yrs

Quoc Le-Nguyen

TITLE
Chief Technical Operations Officer & Head of Quality
COMPENSATION
$631K
AGE
51
TENURE
1 yrs

Hank Mansbach

TITLE
Chief Medical Officer
COMPENSATION
$765K
AGE
54
TENURE
1.3 yrs

Ryan Martins

TITLE
Chief Financial Officer
AGE
43
TENURE
0.7 yrs

Ram Waisbourd

TITLE
COO & Chief Business Officer
COMPENSATION
$318K
AGE
52
TENURE
1.8 yrs
Board of Directors Tenure

Average tenure and age of the 89bio board of directors in years:

1.9
Average Tenure
51
Average Age
  • The average tenure for the 89bio board of directors is less than 3 years, this suggests a new board.
Board of Directors

Rohan Palekar

TITLE
CEO & Director
COMPENSATION
$1M
AGE
53
TENURE
1.8 yrs

Greg Grunberg

TITLE
Independent Director
AGE
46
TENURE
1.9 yrs

Anat Naschitz

TITLE
Independent Director
AGE
51
TENURE
2.2 yrs

Derek Dirocco

TITLE
Independent Director
AGE
39
TENURE
1.9 yrs

Michael Hayden

TITLE
Independent Director
COMPENSATION
$123K
AGE
68
TENURE
1.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
13. Nov 19 Buy Tomer Kariv Individual 11. Nov 19 11. Nov 19 27,500 $16.00 $440,000
13. Nov 19 Buy RA Capital Management, L.P. Company 11. Nov 19 11. Nov 19 1,500,000 $16.00 $24,000,000
13. Nov 19 Buy Genworks 2 Consulting Inc Company 11. Nov 19 11. Nov 19 18,750 $16.00 $300,000
13. Nov 19 Buy Longitude Capital Management Co., LLC Company 11. Nov 19 11. Nov 19 575,000 $16.00 $9,200,000
13. Nov 19 Buy OrbiMed Advisors LLC Company 11. Nov 19 11. Nov 19 837,500 $16.00 $13,400,000
13. Nov 19 Buy Pontifax Ltd. Company 11. Nov 19 11. Nov 19 222,500 $16.00 $3,560,000
X
Management checks
We assess 89bio's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. 89bio has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ETNB News

Simply Wall St News

ETNB Company Info

Description

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, an engineered glycoPEGylated analog of fibroblast growth factor 21 that is in proof of concept Phase 1b/2a clinical trial in patients with nonalcoholic steatohepatitis (NASH) or nonalcoholic fatty liver diseases with a high risk of NASH. The company also focuses on the development and commercialization of other therapies related to NASH, and other liver and cardio-metabolic diseases. 89bio, Inc. was founded in 2018 and is headquartered in San Francisco, California.

Details
Name: 89bio, Inc.
ETNB
Exchange: NasdaqGM
Founded: 2018
$442,764,212
13,788,982
Website: http://www.89bio.com
Address: 89bio, Inc.
142 Sansome Street,
Second Floor,
San Francisco,
California, 94104,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM ETNB Common Stock Nasdaq Global Market US USD 11. Nov 2019
Number of employees
Current staff
Staff numbers
20
89bio employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 03:43
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/19
Last earnings filing: 2020/03/18
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.